文献速递肝病

MASLD/MetALD与具有任意心血管代谢危险因素个体的死亡率:一项随访26.7年的人群研究

MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
PubMed 文献 · Hepatology · 2024-05-13

该研究基于第三次美国国家健康与营养调查的10750名具有任意心血管代谢危险因素的参与者,比较MASLD、MetALD与无脂肪性肝病组间的全因及特定病因死亡风险。随访26年显示,MASLD组全因、心血管及癌症死亡风险较无SLD组无显著增加,而MetALD组全因、癌症及肝脏死亡风险升高,且在FIB-4评估的进展期纤维化者中更明显。

要点

  • 在具有任意心血管代谢危险因素的个体中,单纯MASLD未显著增加全因、心血管或癌症死亡风险。
  • MetALD与全因(HR 1.41)、癌症(HR 2.35)及肝脏(HR 15.04)死亡风险升高相关。
  • MetALD组中经FIB-4评估的进展期纤维化者死亡风险趋势更明显。

核心结论

  • 在具有心血管代谢危险因素的个体中,单纯脂肪性肝病(MASLD)不增加死亡风险,但更多饮酒者(MetALD)死亡风险增加。
  • 控制代谢危险因素并减少MASLD或MetALD患者的饮酒量对改善长期健康结局至关重要。

研究设计与样本

  • 基于人群的队列研究,使用第三次美国国家健康与营养调查的10750名参与者。
  • 采用复杂抽样设计权重的Cox比例风险模型,校正混杂因素后比较MASLD、MetALD与无SLD组的全因及特定病因死亡风险。

主要发现

  • 在具有任意心血管代谢危险因素的个体中,随访26年,MASLD组较无SLD组的全因死亡风险无显著增加(校正HR 1.04,95%CI 0.95-1.14,p=0.413)。
  • MASLD组较无SLD组的心血管死亡风险无显著差异(HR 0.88,95%CI 0.75-1.04,p=0.139)。
  • MASLD组较无SLD组的癌症死亡风险无显著差异(HR 1.06,95%CI 0.84-1.33,p=0.635)。
  • MetALD组较无SLD组的全因死亡风险升高(HR 1.41,95%CI 1.05-1.89,p=0.022)。
  • MetALD组较无SLD组的癌症死亡风险升高(HR 2.35,95%CI 1.33-4.16,p=0.004),肝脏死亡风险升高(HR 15.04,95%CI 2.96-76.35,p=0.002)。

临床怎么用

  • 作者认为,控制代谢危险因素并减少MASLD或MetALD患者的饮酒量将是改善长期健康结局的关键步骤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: A new term, metabolic dysfunction-associated steatotic liver disease (MASLD), has been proposed by a multi-society expert panel. However, it remains unclear whether hepatic steatosis per se in MASLD contributes to an increased risk of mortality in individuals with any cardio-metabolic risk factor (CMRF), which is also a significant risk factor for increased mortality. This study aimed to compare all-cause and cause-specific mortality between the "MASLD/MetALD" and "no steatotic liver disease (SLD)" groups in individuals with any CMRF. APPROACH AND RESULTS: A population-based cohort study was conducted using 10,750 participants of the Third National Health and Nutrition Examination Survey. All-cause and cause-specific (cardiovascular, cancer, diabetes, and liver) mortality risks were compared between the "MASLD," "MetALD," and "no SLD" groups using the Cox proportional hazards model with complex survey design weights, adjusted for confounders. Over 26 years, the "MASLD" group did not show significantly increased all-cause (adjusted HR 1.04[95% CI: 0.95-1.14], p = 0.413), cardiovascular (0.88 [0.75-1.04], p = 0.139), or cancer (1.06[0.84-1.33], p = 0.635) mortality risk compared to the "no SLD" group in individuals with any CMRF. The MetALD group was associated with increased all-cause (1.41 [1.05-1.89], p = 0.022), cancer (2.35 [1.33-4.16], p = 0.004), and liver (15.04 [2.96-76.35], p = 0.002) mortality risk compared with the no SLD group. This trend was more pronounced in the MetALD group with advanced fibrosis assessed by Fibrosis-4 (FIB-4). CONCLUSIONS: In individuals with CMRF, the presence of steatotic liver disease (MASLD) alone did not increase the risk of mortality, except in cases with more alcohol consumption (MetALD). Therefore controlling metabolic risk factors and reducing alcohol consumption in people with MASLD or MetALD will be crucial steps to improve long-term health outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kwak M, Kim HS, Jiang ZG, et al. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up. Hepatology. 2024. PMID: 38739848. doi:10.1097/HEP.0000000000000925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。